AbbVie Evaluates Vitiligo Comorbidities Using the IHD Analytics Platform
An AbbVie research team used Panalgo's IHD Analytics platform to investigate health conditions co-occurring with vitiligo, a chronic autoimmune disorder affecting "about 1 percent of the population worldwide," analyzing data from a large U.S. commercial claims database. The page confirms findings and sensitivity analyses were produced but does not detail specific numerical results — full methodology and outcomes require downloading the PDF.
Norstella is a holding company merging several pharma-intelligence brands — Citeline (trial intelligence), Evaluate (forecasting), MMIT (payer/formulary data) and Panalgo (real-world analytics) — into one data asset.
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Published by Norstella on its own site — read the original case study on panalgo.com ↗
Note: Landing page; specific numeric findings not visible on page, gated behind PDF download
Related use cases
- 01Empowering Early Disease Diagnosis with Real-World Data
- 02Refining Rare Disease Targeting with Real-World Data
- 03Gain Real-Time Insights on High-Risk Patient Populations with Real-World Data
- 04Powering Unbiased Outcomes Research with Longitudinal Data
- 05NorstellaLinQ: Better Together: Getting the Full Patient Picture
- 06Trial Rescue & Reconnaissance